Search clinical trials for: Orelabrutinib,Rituximab and Methotrexate

Total 4419 results

Sun Yat-sen University

Recruiting

Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)

Follicular Lymphoma | Relapsed and Refractory Follicular Lymphoma

China
Affiliated Hospital to Academy of Military Medical...

Recruiting

Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL) (RMO)

Primary Central Nervous System Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma

Relapsed/Refractory Marginal Zone Lymphoma

China
Shandong Provincial Hospital

Recruiting

Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | B-cell NonHodgkin Lymphoma

China
InnoCare Pharma Inc.

Not yet recruiting

A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL

Mantle Cell Lymphoma
Ruijin Hospital

Recruiting

Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement

CNS Lymphoma

China
Peking University People's Hospital

Not yet recruiting

A Study of Orelabrutinib in Patients With ITP

Immune Thrombocytopenia

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Part 1：r/r B-cell Malignancies | Part 2：B-cell Malignancies

United States, Poland, Israel, Ukraine
Tianjin Medical University Cancer Institute and...

Recruiting

A Study of OLR in First-line Treatment of Mantle Cell Lymphoma

Mantle Cell Lymphoma

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma

China
Fudan University

Recruiting

Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma

Helicobacter Pylori Infection | MALT Lymphoma of Stomach

China
The First Affiliated Hospital of Soochow University

Recruiting

Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Diffuse Large B-Cell Lymphoma

China
Peking University People's Hospital

Recruiting

Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors

B-cell Lymphoma

China
Nanfang Hospital, Southern Medical University

Not yet recruiting

Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL (CLL-OBG)

CLL/SLL

China
Huashan Hospital

Active, not recruiting

A Retrospective Study of Newly-diagnosed PCNSL Treated With a Methotrexate (MTX) and Orelabrutinib-based Regimen

Primary Central Nervous System Lymphoma

China
Shandong Cancer Hospital and Institute
The First Affiliated Hospital of Nanchang University

Recruiting

A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma

The First Affiliated Hospital of Nanchang University

China
Huashan Hospital

Active, not recruiting

A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL (ORMD2021)

Primary Central Nervous System Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects

Healthy Subject

China
Hoffmann-La Roche

Terminated

A Study of Efficacy of Rituximab [Mabthera/Rituxan] in Patients With Rheumatoid Arthritis Using Magnetic Resonance Imaging of the Hand (RESONAR)

Rheumatoid Arthritis

Spain
Peking Union Medical College Hospital
Beijing Tiantan Hospital; Capital Medical University

Recruiting

Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL

Primary Central Nervous System Lymphoma

China
Sun Yat-sen University

Not yet recruiting

Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma (O-Gemox)

DLBCL

China
OHSU Knight Cancer Institute
National Cancer Institute (NCI); Oregon Health and Science University

Active, not recruiting

Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma

Central Nervous System Lymphoma

United States
Mirati Therapeutics Inc.

Completed

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

Lymphoma

United States, Canada
Genentech, Inc.
Roche Pharma AG

Completed

Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis
Hoffmann-La Roche

Completed

A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate

Rheumatoid Arthritis

Morocco
Genentech, Inc.

Completed

A Study of Retreatment With Rituximab in Patients With Rheumatoid Arthritis Receiving Background Methotrexate (SUNRISE)

Rheumatoid Arthritis
International Extranodal Lymphoma Study Group (IELSG)

Completed

Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma

Lymphoma, B Cell

Switzerland
OHSU Knight Cancer Institute
AbbVie; Oregon Health and Science University

Recruiting

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

B Acute Lymphoblastic Leukemia | Recurrent B Acute Lymphoblastic Leukemia | Recurrent Mixed Phenotype Acute Leukemia | B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Mixed Phenotype Acute Leukemia

United States
Memorial Sloan Kettering Cancer Center
Pharmacyclics LLC.; Janssen Biotech, Inc.

Recruiting

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) | Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

United States
Fudan University

Not yet recruiting

A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients (C-R-HDMTX)

Central Nervous System Lymphoma
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Recurrent Diffuse Large B-Cell Lymphoma | CD20 Positive | T-Cell Non-Hodgkin Lymphoma

United States
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma (BLOCAGE-01)

Primary Central Nervous System Lymphoma

France
Fred Hutchinson Cancer Center

Terminated

Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | KSHV-associated Multicentric Castleman Disease

Uganda
Dana-Farber Cancer Institute
Genentech, Inc.; Biogen

Completed

Rituximab for Prevention of Chronic GVHD

Hematological Malignancies

United States
Hoffmann-La Roche
Biogen

Completed

A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies

Rheumatoid Arthritis

Belgium, Germany, Norway, United Kingdom, United States, Ireland, France, Canada, Israel, Netherlands, Italy
Second Affiliated Hospital, School of Medicine,...
Ningbo Medical Center Lihuili Hospital; Huizhou Municipal Central Hospital; Taizhou... and other collaborators

Recruiting

Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI

Diffuse Large B-cell Lymphoma

China
The First Affiliated Hospital of Soochow University

Recruiting

Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients

Diffuse Large B Cell Lymphoma

China
Alexion Pharmaceuticals, Inc.

Not yet recruiting

Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)

Hypophosphatasia
Peking University

Recruiting

R-MTX-zanbrutinib in Secondary CNS Lymphoma

Secondary Central Nervous System Lymphoma

China
National Cancer Institute (NCI)

Suspended

Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma

Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

United States
Celgene

Active, not recruiting

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

Neoplasms

United States, France, Australia, Canada, Italy, Korea, Republic of, Spain, United Kingdom
Hoffmann-La Roche

Completed

A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

Belgium, Italy, Poland, Spain, Germany, United Kingdom, Canada, Israel, Australia, Netherlands, Czech Republic
Shanghai Miracogen Inc.

Not yet recruiting

A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN

Squamous Cell Carcinoma of the Head and Neck

China
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

EBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular... and other conditions

United States
Pfizer

Completed

Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)

Rheumatoid Arthritis

United States, Australia, Canada, Israel, Mexico, Colombia, Germany, Russian Federation, South Africa, United Kingdom
Mabion SA
Parexel

Withdrawn

MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis (MABRIDGE)

Rheumatoid Arthritis
Klinikum Stuttgart
German Federal Ministry of Education and Research; University Hospital Freiburg

Recruiting

OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma (OptiMATe)

Primary Central Nervous System Lymphoma

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma

Ann Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular Lymphoma

United States
National Cancer Institute (NCI)

Completed

Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditions

United States

Search clinical trials for: Orelabrutinib,Rituximab and Methotrexate

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations